Oxytocin infusion for maintenance of uterine tone under prophylactic phenylephrine infusion for prevention of post-spinal hypotension in cesarean delivery: a prospective randomised double-blinded dose-finding study.
Cesarean delivery
Hypotension
Oxytocin
Phenylephrine
Uterine tone
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
06 Dec 2023
06 Dec 2023
Historique:
received:
09
08
2023
accepted:
29
11
2023
medline:
11
12
2023
pubmed:
7
12
2023
entrez:
6
12
2023
Statut:
epublish
Résumé
Prior studies have shown that, when administered as an intravenous bolus to prevent uterine atony, prophylactic phenylephrine infusion increased the dose requirement of oxytocin and second-line uterotonics. For the prevention of uterine atony, oxytocin should be delivered by continuous infusion. Here, we aimed to determine the ED50 and ED90 parameters (the effective doses for 50 and 90% patients without uterine atony) of oxytocin for co-infusion with prophylactic phenylephrine during cesarean delivery. In this prospective randomized double-blinded dose-finding study, one hundred patients were divided into four groups to receive 2.5, 5.0, 7.5, or 10 IU/h oxytocin infusion, after the umbilical cord was clamped during the study period. The uterine tone was evaluated and defined as either adequate or inadequate. Probit regression analysis was applied to calculate the ED50 and ED90 of oxytocin infusion. Uterine tone, the percentage of patients who needed additional oxytocin bolus, second-line uterotonics, side effects, estimated blood loss, and neonatal outcomes were monitored. The estimated ED50 and ED90 values of the oxytocin infusion doses for the prevention of uterine atony were 1.9 IU/h (95% CI -4.6-3.8) IU/h and 9.3 IU/h (95% CI 7.3-16.2) IU/h, respectively. Across groups, there was a significant linear trend between the infusion dose and the percentage of patients who required additional oxytocin (p-value = 0.002). No differences were observed in the incidence of side effects and neonatal outcomes. Under the conditions of this study, the ED90 of oxytocin infusion for the prevention of uterine atony was 9.3 IU/h, which is higher than the current recommendation. This finding is helpful for clinical practice, because of the routine use of phenylephrine in cesarean delivery. Further studies are needed to determine the appropriate initial bolus of oxytocin after neonatal delivery. The study was registered on the Chinese Clinical Trial Register (register no. ChiCTR2200059556 ).
Sections du résumé
BACKGROUND
BACKGROUND
Prior studies have shown that, when administered as an intravenous bolus to prevent uterine atony, prophylactic phenylephrine infusion increased the dose requirement of oxytocin and second-line uterotonics. For the prevention of uterine atony, oxytocin should be delivered by continuous infusion. Here, we aimed to determine the ED50 and ED90 parameters (the effective doses for 50 and 90% patients without uterine atony) of oxytocin for co-infusion with prophylactic phenylephrine during cesarean delivery.
METHODS
METHODS
In this prospective randomized double-blinded dose-finding study, one hundred patients were divided into four groups to receive 2.5, 5.0, 7.5, or 10 IU/h oxytocin infusion, after the umbilical cord was clamped during the study period. The uterine tone was evaluated and defined as either adequate or inadequate. Probit regression analysis was applied to calculate the ED50 and ED90 of oxytocin infusion. Uterine tone, the percentage of patients who needed additional oxytocin bolus, second-line uterotonics, side effects, estimated blood loss, and neonatal outcomes were monitored.
RESULTS
RESULTS
The estimated ED50 and ED90 values of the oxytocin infusion doses for the prevention of uterine atony were 1.9 IU/h (95% CI -4.6-3.8) IU/h and 9.3 IU/h (95% CI 7.3-16.2) IU/h, respectively. Across groups, there was a significant linear trend between the infusion dose and the percentage of patients who required additional oxytocin (p-value = 0.002). No differences were observed in the incidence of side effects and neonatal outcomes.
CONCLUSION
CONCLUSIONS
Under the conditions of this study, the ED90 of oxytocin infusion for the prevention of uterine atony was 9.3 IU/h, which is higher than the current recommendation. This finding is helpful for clinical practice, because of the routine use of phenylephrine in cesarean delivery. Further studies are needed to determine the appropriate initial bolus of oxytocin after neonatal delivery.
TRIAL REGISTRATION
BACKGROUND
The study was registered on the Chinese Clinical Trial Register (register no. ChiCTR2200059556 ).
Identifiants
pubmed: 38057742
doi: 10.1186/s12884-023-06165-5
pii: 10.1186/s12884-023-06165-5
pmc: PMC10698888
doi:
Substances chimiques
Oxytocin
50-56-6
Phenylephrine
1WS297W6MV
Oxytocics
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
840Informations de copyright
© 2023. The Author(s).
Références
Anaesthesia. 2019 Oct;74(10):1305-1319
pubmed: 31347151
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Curr Opin Anaesthesiol. 2017 Jun;30(3):319-325
pubmed: 28277383
BMJ. 2011 Aug 01;343:d4661
pubmed: 21807773
Eur J Obstet Gynecol Reprod Biol. 2008 Mar;137(1):27-30
pubmed: 17544563
Can J Anaesth. 2010 Jun;57(6):578-82
pubmed: 20238255
Anesth Analg. 2017 Mar;124(3):857-862
pubmed: 28212181
Br J Anaesth. 2007 Jan;98(1):116-9
pubmed: 17142825
Obstet Gynecol. 2017 Oct;130(4):e168-e186
pubmed: 28937571
Can J Anaesth. 2018 Mar;65(3):254-262
pubmed: 29209926
BJOG. 2010 Jan;117(1):76-83
pubmed: 19781043
Anaesthesia. 2021 Jul;76(7):918-923
pubmed: 33227150
Front Pharmacol. 2021 Oct 20;12:720906
pubmed: 34744714
Anaesthesia. 2018 Jan;73(1):71-92
pubmed: 29090733
Br J Anaesth. 2008 Dec;101(6):822-6
pubmed: 18845650
Anesth Analg. 2010 Dec;111(6):1460-6
pubmed: 20889945
Anesth Analg. 2015 Jul;121(1):159-164
pubmed: 25902327
Sci Rep. 2018 Aug 3;8(1):11666
pubmed: 30076382
Anesth Analg. 2022 Feb 1;134(2):303-311
pubmed: 34469334
BJOG. 2017 Apr;124(5):e106-e149
pubmed: 27981719
Anesth Analg. 2020 Jan;130(1):187-193
pubmed: 30829668
Br J Anaesth. 2010 Mar;104(3):338-43
pubmed: 20150347
BMC Pregnancy Childbirth. 2019 Dec 31;20(1):6
pubmed: 31892352
Anesthesiology. 2015 Jul;123(1):92-100
pubmed: 25909969
Obstet Gynecol. 2004 Nov;104(5 Pt 1):1005-10
pubmed: 15516392